Table 6

Associations between the use of Azathioprine or 6-mercaptopurine and patient and treatment characteristics for patients with Crohn's disease

Characteristics

% reporting Aza/6 MP

Odds ratio

95% CI


Sex

Male

23.5

Referent

Female

23.8

1.0

0.8 to 1.3

Age

16–24

45.3

Referent

25–40

29.0

0.5

0.3 to 0.8

41–55

22.3

0.4

0.2 to 0.6

>55

15.0

0.2

0.1 to 0.4

Disease activity

Inactive

19.2

Referent

Mild

18.5

1.0

0.7 to1.3

Moderate

26.6

1.5

1.1 to 2.1

Severe

38.2

2.6

1.7 to 3.9

Hospitalizations Past 5 Years

None

17.4

Referent

1 – 2

26.1

1.7

1.3 to 2.2

> 2

38.8

3.0

2.2 to 4.1

Surgery within the past 2 years

No

21.3

Referent

Yes

38.0

2.3

1.7 to 3.0

IV Steroids in past 12 months

No

22.8

Referent

Yes

41.1

2.4

1.5 to 3.7

PO Steroids in past 12 months

No

16.6

Referent

Yes

37.1

3.0

2.4 to 3.7

Combined family income before taxes ($)

< 20,000

27.6

Referent

21,000–40,000

18.8

0.6

0.4 to1.0

41,000–60,000

24.7

0.9

0.5 to1.4

61,000–80,000

26.9

0.9

0.6 to 1.6

> 80,000

25.5

0.9

0.6 to 1.4

Prefer not to answer

21.4

0.7

0.4 to 1.2

Region

Maritimes

21.0

Referent

Quebec

28.2

1.5

0.9 to 2.5

Ontario

23.6

1.2

0.7 to 1.9

Prairies

22.0

1.1

0.6 to 1.8

West Coast

22.6

1.1

0.6 to 2.0


Hilsden et al. BMC Gastroenterology 2003 3:10   doi:10.1186/1471-230X-3-10

Open Data